JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), ...

GRANIX (tbo-filgrastim) Injection Teva announced that the FDA has approved Tbo-filgrastim (XM02 filgrastim injection solution), the first granulocyte colony-stimulating factor (G-CSF) to be approved ...

The use of filgrastim vs pegfilgrastim in the auto-SCT population has been studied after high-dose melphalan in multiple myeloma patients. There were no differences in duration of grade 4 neutropenia ...

New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By ...

First New Treatment for Neutropenia Approved in the United States in 10 YearsMarks First Supportive Care Therapy for Cancer Patients from Teva Oncology JERUSALEM, Aug 30, 2012 -- Teva Pharmaceutical ...

PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...

SCF has been shown to synergize with G-CSF to mobilize CD34 + PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to ...

Dublin, Jan. 21, 2022 (GLOBE NEWSWIRE) -- The "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" ...